Evidence map›Paper›PMID 37775270›Full record

ArticleLife science alliance2023

Cost-effective DNA methylation profiling by FML-seq.

Joseph W Foley, Shirley X Zhu, Robert B West

Abstract read
In one paragraph

Article in Life science alliance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Health equity engineering: Optimizing hope for a new generation of healthcare.Journal of clinical and translational science · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Joseph W FoleyDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA jwfoley@nus.edu.sg.ORCID 0000-0002-1579-5286
Shirley X ZhuDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Robert B WestDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.

Funding

Genomic and Morphologic Predictor of High-Risk DCISR01CA193694 · NCI · STANFORD UNIVERSITY · PI WEST, ROBERT B · 2016 to 2020
$3.5M
NCI NIH HHS R01 CA193694
6 · The paper itself

Abstract

Current methods for profiling DNA methylation require costly reagents, sequencing, and labor time. We introduce fragmentation at methylated loci and sequencing (FML-seq), a sequencing library protocol that greatly reduces all these costs. Relative to other techniques tested on the same human cell lines, FML-seq produces similar measurements of absolute and differential cytosine methylation at a fraction of the price. FML-seq enables inexpensive, high-throughput experimental designs for large-scale epigenetics research projects.

Indexed as

DNA MethylationFluorometholoneCost-Benefit AnalysisCpG IslandsEpigenesis, GeneticHumansFluorometholone

Identifiers

PMID37775270
PMCPMC10546043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.